# Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

> **NCT02798536** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 21 (actual)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** LMB-100
- **DRUG:** nab-paclitaxel

## Key facts

- **NCT ID:** NCT02798536
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-27
- **Primary completion:** 2017-07-20
- **Final completion:** 2022-04-21
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02798536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02798536, "Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02798536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*